| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression
Li Li, Fangfang Nan, Qingzhi Guo, Dongdong Guan, Chao Zhou
Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China
Correspondence Address:
Li Li,
Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, Binzhou, Shandong 256603
P.R. China
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/0973-1482.204896
|
|
|
Aim of Study: Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined.
Materials and Methods: In this study, we used ovarian xenograft model to evaluate the underlying resistance mechanisms of BV in ovarian cancer treatment.
Results: Our results showed that EphB4 was overexpressed in BV-resistant xenograft models instead of other common receptor tyrosine kinases. In addition, when coadministrated with EphB4 blocker NVP-BHG712, the antitumor effect of BV was significantly enhanced in the resistant model, further confirmed the role of EphB4 in BV-resistant ovarian cancer. These results indicate that NVP-BHG712 reverses EphB4 overexpression-mediated resistance to BV.
Conclusion: These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.
|
|
|
|
|
|
|
Search Pubmed for